By Spondylitis Association of America
A person’s genetic makeup, including HLA-B27, is thought to make up roughly 90% of the disease risk in ankylosing spondylitis (AS.)1 It’s not surprising then that ethnicity plays a large role in the frequency of AS throughout the world. New research now suggests that ethnicity may also play a role in disease activity and severity.
A phase 3 clinical trial is now recruiting non-radiographic axial Spondyloarthritis (nr-axSpA) patients over the age of 18 to participate in a study of an investigational biologic medication, secukinumab, given by injection.
By The George Washington University
In an increasingly connected and busy world, workers in many fields complain about working themselves “to death” in an attempt to “have it all.” While the phrase is often meant as hyperbole, studies continue to find that heavy workloads, family stressors, decreased free time and unhealthy personal habits really are dangerous for our health.
On November 4, 2017 the Spondylitis Association of America hosted a free Spondylitis Educational Seminar in San Diego, CA. Our speakers for the day were Rheumatologist John Reveille, MD and Physical Therapist Angelo Papachristos, MBA, BSc (PT).
As of December 1, 2017, the FDA has officially approved Taltz injection 80 mg/mL for treatment of patients with active psoriatic arthritis.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.